Subtopic Deep Dive
Radiotherapy for Glioblastoma
Research Guide
What is Radiotherapy for Glioblastoma?
Radiotherapy for Glioblastoma uses ionizing radiation protocols combined with chemotherapy to target glioblastoma multiforme tumors while managing radioresistance and recurrence.
Standard treatment involves 60 Gy in 30 fractions with concomitant and adjuvant temozolomide, as established by the EORTC-NCIC trial (Stupp et al., 2005, 20954 citations). Five-year analysis confirmed median survival of 14.6 months versus 12.1 months with radiotherapy alone (Stupp et al., 2009, 7649 citations). Combined modality trials assess bevacizumab and tumor-treating fields with radiotherapy.
Why It Matters
Radiotherapy with temozolomide sets the survival standard for glioblastoma, extending median survival by 2.5 months with low toxicity (Stupp et al., 2005). Bevacizumab added to radiotherapy-temozolomide improves progression-free survival but not overall survival, guiding first-line decisions (Chinot et al., 2014; Gilbert et al., 2014). Tumor-treating fields plus temozolomide post-radiotherapy further prolongs survival in recurrent cases (Stupp et al., 2017). These advances refine multimodal protocols for this lethal cancer with high recurrence rates.
Key Research Challenges
GBM Stem Cell Radioresistance
Glioblastoma stem cells resist radiotherapy due to enhanced DNA repair and hypoxia (Furnari et al., 2007). Overcoming this requires targeting pathways like IDH mutations that influence radiation sensitivity (Yan et al., 2009). Trials show limited penetration of agents into tumor niches.
Optimizing Dose Fractionation
Balancing 60 Gy standard fractionation against hypofractionation risks normal brain toxicity (Stupp et al., 2005). Long-term data reveal pseudoprogression complicating response assessment (Stupp et al., 2009). Personalized dosing based on MGMT status remains unresolved.
Imaging Response Assessment
Distinguishing radiation necrosis from true progression challenges RANO criteria application (Gilbert et al., 2014). Bevacizumab trials highlight progression-free survival gains without overall survival benefit, needing advanced MRI (Chinot et al., 2014). Functional imaging integration lags in protocols.
Essential Papers
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · 2005 · New England Journal of Medicine · 21.0K citations
The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp, Monika E. Hegi, Warren Mason et al. · 2009 · The Lancet Oncology · 7.6K citations
<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas
Hai Yan, D. Williams Parsons, Genglin Jin et al. · 2009 · New England Journal of Medicine · 5.8K citations
Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur in a majority of several types of malignant gliomas.
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert, James J. Dignam, Terri S. Armstrong et al. · 2014 · New England Journal of Medicine · 2.7K citations
First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma. Progression-free survival was prolonged but did not reach the prespecified improvement ...
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Olivier Chinot, Wolfgang Wick, Warren Mason et al. · 2014 · New England Journal of Medicine · 2.4K citations
The addition of bevacizumab to radiotherapy-temozolomide did not improve survival in patients with glioblastoma. Improved progression-free survival and maintenance of baseline quality of life and p...
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
Roger Stupp, Sophie Taillibert, Andrew A. Kanner et al. · 2017 · JAMA · 2.4K citations
clinicaltrials.gov Identifier: NCT00916409.
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Frank B. Furnari, Tim R. Fenton, Robert Bachoo et al. · 2007 · Genes & Development · 2.3K citations
Malignant astrocytic gliomas such as glioblastoma are the most common and lethal intracranial tumors. These cancers exhibit a relentless malignant progression characterized by widespread invasion t...
Reading Guide
Foundational Papers
Start with Stupp et al. (2005) for RT-TMZ protocol establishing 14.6-month median survival; follow with Stupp et al. (2009) 5-year analysis confirming long-term benefits; Chinot et al. (2014) and Gilbert et al. (2014) for bevacizumab limitations.
Recent Advances
Stupp et al. (2017) on tumor-treating fields extending survival post-RT; Tan et al. (2020) for state-of-art management integrating modern trials.
Core Methods
External beam RT at 2 Gy/fraction to 60 Gy; concomitant TMZ 75 mg/m² daily; adjuvant TMZ 150-200 mg/m² cycles (Stupp et al., 2005). RANO criteria for response; perfusion MRI for necrosis differentiation.
How PapersFlow Helps You Research Radiotherapy for Glioblastoma
Discover & Search
Research Agent uses searchPapers and citationGraph on Stupp et al. (2005) to map 20k+ citing works on radiotherapy-temozolomide, revealing bevacizumab extensions (Chinot et al., 2014). exaSearch queries 'GBM radioresistance fractionation trials' for 500+ recent protocols. findSimilarPapers expands from Stupp et al. (2009) to IDH-related radiation studies.
Analyze & Verify
Analysis Agent applies readPaperContent to Stupp et al. (2005) abstracts for survival curves, then runPythonAnalysis extracts Kaplan-Meier data via pandas for statistical comparison (HR 0.63 verification). verifyResponse with CoVe cross-checks claims against EORTC-NCIC trial using GRADE grading for high evidence quality. Python sandbox computes MGMT methylation impacts from Tan et al. (2020).
Synthesize & Write
Synthesis Agent detects gaps in bevacizumab survival data across Gilbert (2014) and Chinot (2014), flagging contradictions. Writing Agent uses latexEditText for protocol tables, latexSyncCitations for 10-paper bibliographies, and latexCompile for review manuscripts. exportMermaid visualizes trial flowcharts from Stupp trials.
Use Cases
"Extract survival data from Stupp 2005 and compute hazard ratios with Python."
Research Agent → searchPapers('Stupp temozolomide radiotherapy') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas parsing of KM curves) → statistical output with HR, CI, p-values.
"Draft LaTeX review of radiotherapy fractionation in GBM trials."
Synthesis Agent → gap detection on Stupp (2005,2009) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(15 papers) → latexCompile → PDF with trial diagrams.
"Find code for GBM radiotherapy dosimetry models from papers."
Research Agent → paperExtractUrls from Tan (2020) → paperFindGithubRepo(dosimetry scripts) → githubRepoInspect → Code Discovery workflow outputs Python models for dose optimization.
Automated Workflows
Deep Research workflow scans 50+ papers from Stupp et al. (2005) citations, generating structured reports on fractionation evolution with GRADE scores. DeepScan applies 7-step analysis to Chinot (2014), verifying bevacizumab PFS claims via CoVe checkpoints. Theorizer hypothesizes IDH1/2 radio-modulation strategies from Yan (2009) and Stupp data.
Frequently Asked Questions
What defines standard radiotherapy for glioblastoma?
60 Gy in 30 fractions with concomitant and adjuvant temozolomide, per EORTC-NCIC phase III trial (Stupp et al., 2005).
What methods combine radiotherapy with other agents?
Temozolomide concurrent with RT followed by adjuvant cycles (Stupp et al., 2005); bevacizumab added to RT-TMZ (Chinot et al., 2014); tumor-treating fields post-RT (Stupp et al., 2017).
What are key papers on radiotherapy outcomes?
Stupp et al. (2005, 20954 citations) established RT-TMZ survival benefit; 5-year follow-up in Stupp et al. (2009, 7649 citations); bevacizumab trials in Gilbert (2014) and Chinot (2014).
What open problems exist in GBM radiotherapy?
Overcoming stem cell radioresistance (Furnari et al., 2007); improving imaging for pseudoprogression (Stupp et al., 2009); personalizing fractionation beyond MGMT status (Tan et al., 2020).
Research Glioma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Radiotherapy for Glioblastoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Glioma Diagnosis and Treatment Research Guide